Modification of glycosylated haemoglobin concentration during artificial endocrine pancreas treatment of diabetics. Evidence for a short-term effect on HbA 1 (a+b+c) levels.
In order to verify whether or not insulin-induced blood glucose control can acutely lower glycosylated haemoglobin levels, HbAI (a+b+c) (HbAI) was measured in 11 diabetics before, during and after 3 days of treatment with an "artificial endocrine pancreas" (Biostator). Initially 5 patients were in fair glycaemic control (group A), while the other 6 showed poor control (group B). HbAI levels decreased significantly after 3 days in both groups A (from 9.6 +/- 0.2% to 8.5 +/- 0.3%, mean +/- SEM, p less than 0.05) and B (from 13.7 +/- 0.2% to 12.6 +/- 0.3%, p less than 0.05). A further HbAI decrease was observed until day 60 following Biostator treatment, during which period glycaemic control improved, as assessed by fasting and post-lunch plasma glucose values and daily glycosuria determined every 10 days. These results suggest that increased HbAI levels may be reversed early by strict blood glucose control during a 3 day period. It is concluded that HbAI levels not only reflect long-term glycaemic control, but also recent acute variations in mean blood glucose values.
D000293:Adolescent; D000328:Adult; D001187:Artificial Organs; D001786:Blood Glucose / Q000032:analysis; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006027:Glycosides / Q000032:analysis* / Q000097:blood*; D006029:Glycosuria; D006441:Hemoglobin A / Q000031:analogs & derivatives* / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000502:physiology; D008297:Male; D008875:Middle Aged
D001786:Blood Glucose; D006027:Glycosides; D007328:Insulin; D006441:Hemoglobin A